Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Keloid article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
A keloid scar is one in which there is overgrowth of dense fibrous tissue. This usually develops after the injury has healed. It extends beyond the borders of the original wound. It does not normally regress spontaneously and it will usually recur after excision. This contrasts with hypertrophic scars, which stay within the borders of the original wound.
The term 'chéloïde' was coined by Alibert in 1806, from the Greek 'chele', meaning crab's claw - to describe the lateral growth of tissue into unaffected skin.
- Keloid scars are more common in people with darker skins, especially African-American races.
- The incidence in African populations is 6-16%.
- There is equal sex distribution.
- The peak age is 20-30 years and keloids are less common at the extremes of age.
- Half of patients with keloid have a positive family history.
The cause is unknown, although there are various theories, including:
- Dysfunction of the extracellular matrix which controls growth factor activity.
- Abnormalities in collagen turnover.
- An inherited abnormal response to dermal injury.
- An immune reaction to sebum.
- Genetic susceptibility - a genome-wide association study (GWAS) suggested that the common genetic factor predisposing to the development of keloid was shared by the Chinese Han and Japanese populations.
- Hormonal factors - keloid is associated with pregnancy and puberty.
- Symptoms: usually cosmetic, although the scar may be tender, painful, itch or produce a burning sensation.
- There is usually a history of trauma that may be accidental, surgical or cosmetic.
- Sites for keloid formation: the most common areas are the sternum, shoulder, earlobe and cheek.
- Burn scars or infected lesions, including acne, are more likely to form keloids.
- The scar has grown beyond the original line of trauma and may be raised and irregular.
- The texture is rubbery.
- It is red in the early stages but becomes brown or pale with age.
- There are no hair follicles or sweat glands within the scar.
- Keloids over a joint can contract and restrict movement.
- Clinical course - the natural history is variable:
- Most lesions grow for weeks-months but growth can continue for years.
- Growth is usually slow but some keloids can enlarge rapidly over months.
- When they stop growing, they remain stable or regress slightly.
- The diagnosis is made clinically; investigations are not required.
- Assess the patient's concerns and the impact of the scar(s) on their life.
- Check if the scar reduces mobility - eg, near a joint.
Hypertrophic scars are also red and prominent but do not extend beyond the wound border. Hypertrophic scars usually appear within a month of the injury, grow for several months and then regress, whereas keloid scars may appear later and continue growing for longer.
Keloid scars are difficult to treat. There are various options. Reviews suggest that combinations of treatments are probably the most effective.
Intralesional steroid injections, with triamcinolone, are a mainstay of treatment and prevention - reviews suggest that it improves the majority of scars.
- Injections are given every 2-6 weeks until improvement.
- Side-effects: pigment changes, telangiectasias and subcutaneous atrophy (which may resolve).
Steroid-impregnated tape applied for 12 hours/day may flatten keloids.
Pressure or occlusive dressings
These are used both for treatment and prevention, with minimal adverse effects, provided they are practical and acceptable to the patient.
- Silicone gel - this is applied as topical gel or a gel-impregnated sheet.[6, 9]
- Compression earrings - are used after excision of earlobe keloids and give good rates of recurrence-free healing; they should be worn 24 hours/day.
- Other pressure dressings may be used.
Surgical excision on its own has a very high recurrence rate and the recurring scar may even be larger than the original. Results can be improved by:
- Meticulous surgical technique.
- Additional treatments such as intralesional steroids, occlusive or pressure dressings or radiotherapy.
Radiotherapy is recommended, particularly post-surgery for the treatment of keloid scars. There have been concerns about its safety, due to its carcinogenic properties but, providing surrounding tissues are protected, the risk is very low. Implantation of radioactive seeds (brachytherapy) post-surgery was found to be an effective treatment.
Cryotherapy has been used alone and combined with other treatments. Reported results vary:
- Cryotherapy may stop early-stage keloids from growing.
- It may be effective in combination with intralesional steroid.
- Hypopigmentation is a side-effect.
A study reviewing the effects of intralesional cryotherapy is ongoing.
Other possible treatments
- The evidence base supporting the use of lasers in keloid scars is not as large as that supporting their use in hypertrophic scars. Further research is required to determine the mechanism of action for different laser systems and to examine such outcomes as scar erythema, scar texture, degrees of symptom relief, recurrence rates and adverse effects.
- One study reported the successful use of carbon dioxide laser ablation followed by intralesional steroids.
- Pulsed dye lasers and Nd:YAG lasers are reported to give encouraging results, with few adverse effects. However, pulsed dye lasers are less effective on dark skin.Combination treatment of CO2 fractional laser, pulsed dye laser and triamcinolone acetonide injection has been successfully used for refractory keloid scars on the upper back.
- Laser treatment may reduce the redness of keloids without shrinking them.
- A combination of intralesional steroids and intense pulsed light has been found to improve clinical outcome compared with intralesional steroids alone.
- Intralesional interferon alfa-2b has been shown to reduce keloid scars to a greater extent than steroids and may be particularly useful in cases which are resistant to intralesional steroids.
- May be beneficial when used alone or in combination with other treatments.
- Possible side-effects are pain, hypopigmentation and tissue sloughing.
- This cytotoxic agent can be given locally as intralesional injections and improved scars in one small study. Side-effects were hyperpigmentation and dermal atrophy.
- Topical or intralesional retinoids have been used in clinical trials and produced moderate improvements but should not be considered first-line.
Other treatments being explored include mitomycin C, tamoxifen, methotrexate and imiquimod.
For people at high risk of or with a history of keloids:
- Avoid body piercing, tattoos and unnecessary incisions such as cosmetic surgery - particularly to skin sites more prone to keloid formation (see under 'Presentation', above).
- Treat acne thoroughly to reduce lesions and potential for scarring.
- If surgery is required, it may be combined with dressings, intralesional steroids or other treatments (see under 'Management', above) to reduce the likelihood or size of keloid scarring. Care with surgical technique is important.
Further reading and references
Dong X, Mao S, Wen H; Upregulation of proinflammatory genes in skin lesions may be the cause of keloid formation (Review). Biomed Rep. 2013 Nov1(6):833-836. Epub 2013 Sep 25.
Park TH, Park JH, Chang CH; Clinical features and outcomes of foot keloids treated using complete surgical excision and full thickness skin grafting followed by corticosteroid injections. J Foot Ankle Res. 2013 Jul 156(1):26.
Baron Jean-Louis Alibert (1768-1837); Interuniversity Health Library, Paris
Juckett G, Hartman-Adams H; Management of keloids and hypertrophic scars. Am Fam Physician. 2009 Aug 180(3):253-60.
Gauglitz GG, Korting HC, Pavicic T, et al; Hypertrophic Scarring and Keloids: Pathomechanisms, Current and Emerging Treatment Strategies. Mol Med. 2010 Oct 5.
Davidson S, Aziz N, Rashid RM, et al; A primary care perspective on keloids. Medscape J Med. 200911(1):18. Epub 2009 Jan 20.
Zhu F, Wu B, Li P, et al; Association study confirmed susceptibility loci with keloid in the Chinese Han population. PLoS One. 2013 May 78(5):e62377. doi: 10.1371/journal.pone.0062377. Print 2013.
Al-Attar A, Mess S, Thomassen JM, et al; Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006 Jan117(1):286-300.
Leventhal D, Furr M, Reiter D; Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. 2006 Nov-Dec8(6):362-8.
Lebwohl M et al; Treatment of Skin Disease: Comprehensive Therapeutic Strategies, 2013
O'Brien L, Pandit A; Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2006 Jan 25(1):CD003826.
Ogawa R, Yoshitatsu S, Yoshida K, et al; Is radiation therapy for keloids acceptable? The risk of radiation-induced Plast Reconstr Surg. 2009 Oct124(4):1196-201.
De Cicco L, Vischioni B, Vavassori A, et al; Postoperative management of keloids: Low-dose-rate and high-dose-rate brachytherapy. Brachytherapy. 2014 Feb 17. pii: S1538-4721(14)00025-7. doi: 10.1016/j.brachy.2014.01.005.
Bijlard E, Timman R, Verduijn GM, et al; Intralesional cryotherapy versus excision and corticosteroids or brachytherapy for keloid treatment: study protocol for a randomised controlled trial. Trials. 2013 Dec 1914:439. doi: 10.1186/1745-6215-14-439.
Jin R, Huang X, Li H, et al; Laser therapy for prevention and treatment of pathologic excessive scars. Plast Reconstr Surg. 2013 Dec132(6):1747-58. doi: 10.1097/PRS.0b013e3182a97e43.
Garg GA, Sao PP, Khopkar US; Effect of carbon dioxide laser ablation followed by intralesional steroids on keloids. J Cutan Aesthet Surg. 2011 Jan4(1):2-6. doi: 10.4103/0974-2077.79176.
Martin MS, Collawn SS; Combination treatment of CO2 fractional laser, pulsed dye laser, and triamcinolone acetonide injection for refractory keloid scars on the upper back. J Cosmet Laser Ther. 2013 Jun15(3):166-70. doi: 10.3109/14764172.2013.780448. Epub 2013 Apr 29.
Shamsi Meymandi S, Rezazadeh A, Ekhlasi A; Studying intense pulsed light method along with corticosteroid injection in treating keloid scars. Iran Red Crescent Med J. 2014 Feb16(2):e12464. doi: 10.5812/ircmj.12464. Epub 2014 Feb 5.
Lee JH, Kim SE, Lee AY; Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. 2008 Feb47(2):183-6. doi: 10.1111/j.1365-4632.2008.03426.x.
Viera MH, Amini S, Valins W, et al; Innovative therapies in the treatment of keloids and hypertrophic scars. J Clin Aesthet Dermatol. 2010 May3(5):20-6.